ESC 2020: PARALLAX: Sacubitril/Valsartan Shown to Reduce NT-proBNP in HFpEF
Functional capacity was no better than individualized background therapy, however.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.